PepGen Inc. prices $100 million public offering of 31.25 million shares at $3.20 per share

PepGen Inc.

PepGen entered into underwriting agreement with Leerink Partners and Stifel to sell 31,250,000 shares at $3.20 per share.
Underwriters exercised in full their 30-day option to purchase an additional 4,687,500 shares.
Net proceeds estimated at $107.6 million to fund FREEDOM-DM1 and FREEDOM2-DM1 clinical trials and for working capital.
Offering expected to close on September 26, 2025, subject to customary conditions.
Securities offered under an effective shelf registration statement filed with the SEC on June 28, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.